Loading clinical trials...

Facial Papules in Frontal Fibrosing Alopecia (FFA) | Clinical Trials | Clareo Health

NOT_YET_RECRUITINGNA

Facial Papules in Frontal Fibrosing Alopecia (FFA)

Evaluating the Efficacy of the 1726nm Laser for the Treatment of Facial Papules in Frontal Fibrosing Alopecia (FFA)

NCT07340671•University of Miami

Summary

The objective is to evaluate the safety and efficacy of the Cutera 1726 nm laser system (also referred to as AviClear) for the treatment of facial papules in frontal fibrosing alopecia (FFA).

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Female or Male
•Fitzpatrick Skin Types I-VI
•At least 18 years of age
•Has clinically diagnosed FFA with facial papules.
•Subject must be able to read, speak, and understand English or Spanish and sign the Informed Consent Form.
•Willing and able to adhere to the treatment and follow-up schedule and pre/post-treatment care instructions.
•No contraindication to laser therapy.
•Willing to have photographs taken of the treatment area and agree to the use of photographs for presentation, educational or marketing purposes.
•Agree to not undergo any other procedure(s) or add any new treatment modalities in the treatment area during the study.
•Willing to use investigator approved skincare topicals and follow investigator approved skincare regimen for the duration of the study.

Exclusion Criteria

•Prior treatment to the target area during participation in a clinical trial of another device or drug within 1 month (30 days) prior to study participation.
•Prior treatment to the target area within 3 months of study participating including chemical peel, dermabrassion, microneedling, radiofrequency treatment, laser or light-based procedures, cryodestruction or chemodestruction, intralesional steroids, photodynamic therapy, or acne surgery.
•Prior injection of botulinum toxin in the target area within 3 months of study participation and for the duration of the study.
•Systemic use of retinoid, such as isotretinoin, within 3 months of study participation.
•Still healing from another treatment in the target area according to investigator's discretion.
•History of malignant tumors in the target area.
•Pregnant and/or breastfeeding or planning to become pregnant during the study.
•Suffering from diagnosed immunosuppression/immune deficiency disorders or currently using immunosuppressive medications.
•History of diagnosed connective tissue disease, such as systemic lupus erythematosus or scleroderma.
•Any use of medication that is known to increase sensitivity to light according to Investigator's discretion.
+7 more criteria

Locations (1)

University of Miami

Miami, Florida, United States

Key Dates

Start Date

February 1, 2026

Primary Completion Date

December 1, 2028

Completion Date

December 1, 2028

Last Updated

January 14, 2026

Enrollment

ESTIMATED participants

Conditions

Frontal Fibrosing Alopecia

Interventions

Cutera® 1726 nm laser system

DEVICE

Contacts

Maria V Muniz

CONTACT

305-689-2646 mmuniz@med.miami.edu

Leigh Nattkemper, PhD

CONTACT

305-588-9734 lxn202@med.miami.edu

Follicular Revival in Fibrosing Alopecia: Evaluating Use of Micro-needling

NCT04342091

Fibrosing AlopeciaFrontal Fibrosing Alopecia+1 more

View study

UNKNOWNNA

Study to Assess the Efficacy of Intralesional Corticosteroid on the Treatment of Frontal Fibrosing Alopecia

NCT02467101

Frontal Fibrosing Alopecia

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 14, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions